Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342183 | 0.84 | NPC1 (0.56) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL5113764 | 0.83 | NPC1 (0.54) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL948055 | 0.83 | NPC1 (0.53) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL6556065 | 0.83 | NPC1 (0.53) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL7315228 | 0.82 | NPC1 (0.53) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL7283277 | 0.82 | NPC1 (0.52) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL4019038 | 0.81 | NPC1 (0.58) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL949772 | 0.80 | NPC1 (0.51) | NPC1RAB9ACASP3MAOBPOLB | |
| SCHEMBL1909577 | 0.79 | ABCB1 (0.42) | NPC1RAB9ACASP3ALDH1A1LMNA | |
| SCHEMBL7274760 | 0.79 | NPC1 (0.55) | NPC1RAB9ACASP3MAOBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7262211-B2 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262211-B2 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-5668289-A | Pyridinone thrombin inhibitors | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997030708-A1 | PYRIDINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5658930-A | THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656645-A | INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997001338-A1 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
| WO-1996018644-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | NPC1 3660/4885RAB9A 97/4885CASP3 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.